How We Manage Idiopathic Multicentric Castleman Disease

被引：7

作者：

Brandstadter, Joshua D. ^{[1
]}

Fajgenbaum, David C. ^{[2
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA

[2] Univ Penn, Ctr Cytokine Storm Treatment & Lab, Perelman Sch Med, Div Translat Med & Human Genet, Philadelphia, PA 19104 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 09期

关键词：

TREATMENT GUIDELINES; CYCLOSPORINE-A; RITUXIMAB; ANTIBODY; SILTUXIMAB; ANASARCA;

D O I：

10.1245/clin.1248-0124

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：564 / 571

页数：8

共 53 条

[1] Increased mTOR activation in idiopathic multicentric Castleman disease [J].

Arenas, Daniel J. ;

Floess, Katherine ;

Kobrin, Dale ;

Pai, Ruth-Anne Langan ;

Srkalovic, Maya B. ;

Tamakloe, Mark-Avery ;

Rasheed, Rozena ;

Ziglar, Jasira ;

Khor, Johnson ;

Parente, Sophia A. T. ;

Pierson, Sheila K. ;

Martinez, Daniel ;

Wertheim, Gerald B. ;

Kambayashi, Taku ;

Baur, Joseph ;

Teachey, David T. ;

Fajgenbaum, David C. .

BLOOD, 2020, 135 (19) :1673-1684

[2] Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review [J].

Belyaeva, Elizaveta ;

Rubenstein, Ayelet ;

Pierson, Sheila K. ;

Dalldorf, Delaney ;

Frank, Dale ;

Lim, Megan S. ;

Fajgenbaum, David C. .

HEMATOLOGICAL ONCOLOGY, 2022, 40 (02) :191-201

[3]

Chen LYC, 2021, LANCET, V397, P1749, DOI 10.1016/S0140-6736(21)00674-7

[4] POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management [J].

Dispenzieri, Angela .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) :814-829

[5] Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease [J].

Dong, Yujun ;

Zhang, Lu ;

Nong, Lin ;

Wang, Lihong ;

Liang, Zeyin ;

Zhou, Daobin ;

Fajgenbaum, David C. ;

Ren, Hanyun ;

Li, Jian .

ANNALS OF HEMATOLOGY, 2018, 97 (09) :1641-1647

[6] Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) [J].

El-Osta, Hazem ;

Janku, Filip ;

Kurzrock, Razelle .

MOLECULAR CANCER THERAPEUTICS, 2010, 9 (06) :1485-1488

[7] Cytokine Storm [J].

Fajgenbaum, David C. ;

June, Carl H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2255-2273

[8] Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease [J].

Fajgenbaum, David C. ;

Wu, David ;

Goodman, Aaron ;

Wong, Raymond ;

Chadburn, Amy ;

Nasta, Sunita ;

Srkalovic, Gordan ;

Mukherjee, Sudipto ;

Leitch, Heather ;

Jayanthan, Raj ;

Ferrero, Simone ;

Sato, Yasuharu ;

Schey, Steve ;

Dispenzieri, Angela ;

Oksenhendler, Eric ;

Zinzani, Pier Luigi ;

Lechowicz, Mary Jo ;

Hoffmann, Christian ;

Pemmaraju, Naveen ;

Bagg, Adam ;

Fossa, Alexander ;

Lim, Megan S. ;

van Rhee, Frits .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) :1553-1561

[9] Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease [J].

Fajgenbaum, David C. ;

Langan, Ruth-Anne ;

Japp, Alberto Sada ;

Partridge, Helen L. ;

Pierson, Sheila K. ;

Singh, Amrit ;

Arenas, Daniel J. ;

Ruth, Jason R. ;

Nabel, Christopher S. ;

Stone, Katie ;

Okumura, Mariko ;

Schwarer, Anthony ;

Jose, Fabio Freire ;

Hamerschlak, Nelson ;

Wertheim, Gerald B. ;

Jordan, Michael B. ;

Cohen, Adam D. ;

Krymskaya, Vera ;

Rubenstein, Arthur ;

Betts, Michael R. ;

Kambayashi, Taku ;

van Rhee, Frits ;

Uldrick, Thomas S. .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10) :4451-4463

[10] Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease [J].

Fajgenbaum, David C. .

BLOOD, 2018, 132 (22) :2323-2330

← 1 2 3 4 5 6 →